Lysophosphatidic acid-activated Cl- current activity in human systemic sclerosis skin fibroblasts

Rheumatology

Volumn 49, Issue 12, 2010, Pages 2290-2297

  Yin, Zhaohong ^a   Carbone, Laura D ^a   Gotoh, Mari ^a,b   Postlethwaite, Arnold ^a   Bolen, Alyssa L ^a   Tigyi, Gabor J ^a   Murakami murofushi, Kimiko ^b   Watsky, Mitchell A ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b OCHANOMIZU UNIVERSITY   (Japan)

Author keywords

Smooth muscle actin; Cl channel; Fibroblast; Lysophosphatidic acid; Myofibroblast

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; LYSOPHOSPHATIDIC ACID;

ADULT; ARTICLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COLORIMETRY; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE MARKER; ELECTROPHYSIOLOGY; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN TISSUE; MALE; MYOFIBROBLAST; PRIORITY JOURNAL; PROTEIN EXPRESSION; SKIN BIOPSY; SKIN FIBROBLAST; SYSTEMIC SCLEROSIS; WESTERN BLOTTING;

ACTINS; ADULT; ANALYSIS OF VARIANCE; CASE-CONTROL STUDIES; CELLS, CULTURED; CHLORIDES; FEMALE; FIBROBLASTS; HUMANS; LYSOPHOSPHOLIPIDS; MALE; MIDDLE AGED; MUSCLE, SMOOTH; MYOFIBROBLASTS; SCLERODERMA, SYSTEMIC; SKIN;

EID: 78549260067     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keq260     Document Type: Article

References (42)

1. Varga JA, Trojanowska M. Fibrosis in systemic sclerosis. Rheum Dis Clin North Am 2008;34:115-43.
2. Steen V. Targeted therapy for systemic sclerosis. Autoimmun Rev 2006;5:122-4.
3. Jun JB, Kuechle M, Harlan JM, Elkon KB. Fibroblast and endothelial apoptosis in systemic sclerosis. Curr Opin Rheumatol 2003;5:756-60.
4. Abraham DJ, Eckes B, Rajkumar V, Krieg T. New developments in fibroblast and myofibroblast biology: implications for fibrosis and scleroderma. Curr Rheumatol Rep 2007;9:136-43.
5. Gabbiani G. The myofibroblast in wound healing and fibrocontractive diseases. J Pathol 2003;200:500-3.
6. Darby IA, Hewitson TD. Fibroblast differentiation in wound healing and fibrosis. Int Rev Cytol 2007;257:143-79.
7. Hinz B, Phan SH, Thannickal VJ, Galli A, Bochaton-Piallat ML, Gabbiani G. The myofibroblast: one function, multiple origins. Am J Pathol 2007;170:1807-16.
8. Atamas SP, White B. Cytokine regulation of pulmonary fibrosis in scleroderma. Cytokine Growth Factor Rev 2003;14:537-50.
9. Needleman BW, Wigley FM, Stair RW. Interleukin-1, interleukin-2, interleukin-4, interleukin-6, tumor necrosis factor alpha, and interferon-gamma levels in sera from patients with scleroderma. Arthritis Rheum 1992;35:67-72.
10. Sano S, Baker D, Wada A et al. Multiple mechanisms linked to platelet activation result in lysophosphatidic acid and sphingosine-1-phosphate generation in blood. J Biol Chem 2002;277:21197-206.
11. Williams JR, Khandoga AL, Goyal P et al. Unique ligand selectivity of the GPR92/LPA5 lysophosphatidate receptor indicates role in human platelet activation. J Biol Chem 2009;284:17304-19.
12. Ikeda H, Yatomi Y, Yanase M et al. Effects of lysophosphatidic acid on proliferation of stellate cells and hepatocytes in culture. Biochem Biophys Res Commun 1998;248:436-40.
13. Yin Z, Watsky MA. Chloride channel activity in human lung fibroblasts and myofibroblasts. Am J Physiol Lung Cell Mol Physiol 2005;288:L1110-6.
14. Piazza GA, Ritter JL, Baracka CA. Lysophosphatidic acid induction of transforming growth factors alpha and beta: modulation of proliferation and differentiation in cultured human keratinocytes and mouse skin. Exp Cell Res 1995;216:51-64.
15. Sauer B, Vogler R, Zimmermann K et al. Lysophosphatidic acid interacts with transforming growth factor-beta signaling to mediate keratinocyte growth arrest and chemotaxis. J Invest Dermatol 2004;123:840-9.
16. Wang J, Carbone LD, Watsky MA. Receptor-mediated activation of a Cl(-) current by LPA and S1P in cultured corneal keratocytes. Invest Ophthalmol Vis Sci 2002;43:3202-8.
17. Yin Z, Tong Y, Zhu H, Watsky MA. ClC-3 is required for LPA-activated Cl-current activity and fibroblast-to-myofibroblast differentiation. Am J Physiol Cell Physiol 2008;294:C535-42.
18. Masi A. Subcommittee for Scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23:581-90.
19. Rae JL, Cooper KE, Gates P, Watsky MA. Low access perforated patch recordings using amphotericin B. J Neurosci Methods 1991;37:15-26.
20. Milano A, Pendergrass SA, Sargent JL et al. Molecular subsets in the gene expression signatures of scleroderma skin. PLoS ONE 2008;16:3-7.
21. Kirk TZ, Mark ME, Chua CC, Chua BH, Mayes MD. Myofibroblasts from scleroderma skin synthesize elevated levels of collagen and tissue inhibitor of metalloproteinase (TIMP-1) with two forms of TIMP-1. J Biol Chem 1995;270:3423-8.
22. Pradère JP, Gonzalez J, Klein J et al. Lysophosphatidic acid and renal fibrosis. Biochim Biophys Acta 2008;1781:582-7.
23. 1 receptor activation promotes renal interstitial fibrosis. J Am Soc Nephrol 2007;18:3110-8.
24. Tangkijvanich P, Melton AC, Chitapanarux T, Han J, Yee HF. Platelet-derived growth factor-BB and lysophosphatidic acid distinctly regulate hepatic myofibroblast migration through focal adhesion kinase. Exp Cell Res 2002;281:140-7.
25. Watanabe N, Ikeda H, Nakamura K et al. Plasma lysophosphatidic acid level and serum autotaxin activity are increased in liver injury in rats in relation to its severity. Life Sci 2007;81:1009-15.
26. 1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak. Nat Med 2008;14:45-54.
27. Ley K, Zarbock A. From lung injury to fibrosis. Nat Med 2008;14:20-1.
28. Sasagawa T, Suzuki K, Shiota T, Kondo T, Okita M. The significance of plasma lysophospholipids in patients with renal failure on hemodialysis. J Nutr Sci Vitaminol 1998;44:809-18.
29. Akalaev RN, Abidov AA. Phospholipid composition of erythrocytes in patients with chronic kidney failure. Vopr Med Khim 1993;39:43-5.
30. Akhmetshina A, Dees C, Pileckyte M et al. Rho-associated kinases are crucial for myofibroblast differentiation and production of extracellular matrix in scleroderma fibroblasts. Arthritis Rheum 2008;58:2553-64.
31. Watanabe N, Ikeda H, Nakamura K et al. Both plasma lysophosphatidic acid and serum autotaxin levels are increased in chronic hepatitis C. J Clin Gastroenterol 2007;41:616-23.
32. Postlethwaite AE, Chiang TM. Platelet contributions to the pathogenesis of systemic sclerosis. Curr Opin Rheumatol 2007;19:574-9.
33. Seibold JR, Giorno RC, Claman HN. Dermal mast cell degranulation in systemic sclerosis. Arthritis Rheum 1990;33:1702-9.
34. Hashimoto T, Ohata H, Honda K. Lysophosphatidic acid (LPA) induces plasma exudation and histamine release in mice via LPA receptors. J Pharmacol Sci 2006;100:82-7.
35. Ikeda H, Watanabe N, Ishii I et al. Sphingosine 1-phosphate regulates regeneration and fibrosis after liver injury via sphingosine 1-phosphate receptor 2. J Lipid Res 2009;50:556-64.
36. Swaney JS, Moreno KM, Gentile AM, Sabbadini RA, Stoller GL. Sphingosine-1-phosphate (S1P) is a novel fibrotic mediator in the eye. Exp Eye Res 2008;87:367-75.
37. Uhlig S, Gulbins E. Sphingolipids in the lungs. Am J Respir Crit Care Med 2008;178:1100-14.
38. Gellings Lowe N, Swaney JS, Moreno KM, Sabbadini RA. Sphingosine-1-phosphate and sphingosine kinase are critical for transforming growth factor-beta-stimulated collagen production by cardiac fibroblasts. Cardiovasc Res 2009;82:303-12.
39. Tokumura A, Carbone LD, Yoshioka Y et al. Elevated serum level of arachidonoyl-lysophosphatidic acid and sphingosine 1-phosphate in systemic sclerosis. Int J Med Sci 2009;6:168-76.
40. Hafner J, Schneider E, Burg G, Cassina PC. Management of leg ulcers in patients with rheumatoid arthritis or systemic sclerosis: the importance of concomitant arterial and venous disease. J Vasc Surg 2000;32:322-9.
41. Alivernini S, De Santis M, Tolusso B et al. Skin ulcers in systemic sclerosis: determinants of presence and predictive factors of healing. J Am Acad Dermatol 2009;60:426-35.
42. Barrientos S, Stojadinovic O, Golinko MS, Brem H, Tomic-Canic M. Growth factors and cytokines in wound healing. Wound Repair Regen 2008;16:585-601.